- What you will discover...
- Understand the causes of female infertility and explore the pipeline treatments for this disorder
- Assess market revenue and the annual cost of therapy allowing you to strategize for success
- IVF success rates are a huge unmet need in this market and need to be improved
- Although great progress has been made, KOLs interviewed by GlobalData emphasized that there is still room for the standard of care to improve
Female infertility drug market set to reach $2.5bn by 2028
The greatest drivers of growth in the global FI market are a growing number of women are postponing pregnancy until later in life and at a reproductively older age when fertility has generally decreased and the launch of Nolasiban in the US and 5EU, the first major innovation in this indication in many years.
Kelly Lambrinos, MA, Senior Pharma Analyst at GlobalData, explains:
“The fact that a growing number of women are postponing pregnancy until later in life when fertility has generally decreased, will translate into increased use of ART fertility treatments between 2018 and 2028.”
“A limited number of established companies compete in this space, and the strategy has mainly been to create improved versions of existing drugs. As such, the drugs used to treat patients have remained largely unchanged. These include, among others, blockbuster drugs such as EMD Serono’s Gonal-F (follitropin alfa), Merck & Co’s Follistim (follitropin beta) and Ferring Pharmaceuticals’ Menopur (menotropins) which collectively claimed over 50% of the total FI market in 2018.”
Non-surgical treatments, as well as treatments that can be administered less frequently, will be a key focus of this report. Gain in-depth knowledge of products in the pipeline and align your product plans accordingly.
Interested in dominating this market? Click ‘Buy Now’ to explore this report.